MWNA
CPRX icon

Marshall Wace North America’s Catalyst Pharmaceutical CPRX Stock Holding History

Marshall Wace North America’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-105,345
Closed -$329K – 986
2018
Q2 		$329K Buy
+105,345
New +$320K ﹤0.01% 1161
2018
Q1 		– Sell
-168,974
Closed -$661K – 1476
2017
Q4 		$661K Buy
+168,974
New +$558K ﹤0.01% 1084

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Marshall Wace North America's CPRX Position: Q3 2018 in Review

Marshall Wace North America sold out of Catalyst Pharmaceutical (CPRX) in Q3 2018, closing a stake of 105,345 shares — an estimated $329K sold.

Marshall Wace North America first reported a position in CPRX in Q4 2017 and held it in 2 quarters. The position peaked at $661K in Q4 2017. 97 funds tracked by Wall St. Rank hold CPRX as of Q3 2018.

  • Marshall Wace North America reported no remaining Catalyst Pharmaceutical position as of Q3 2018 after selling out during the quarter.
  • Marshall Wace North America sold 105,345 Catalyst Pharmaceutical shares in Q3 2018, an estimated $329K.
  • Marshall Wace North America first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 2 quarters.
  • Marshall Wace North America's Catalyst Pharmaceutical position peaked at $661K in Q4 2017.
  • 97 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2018.

Based on Marshall Wace North America's 13F filing for Q3 2018, filed 14 Nov 2018.